Bioveta

Bioveta operates within the chemicals and manufacturing sectors, specializing in the development and production of veterinary medicaments. The company utilizes advanced biotechnological processes to manufacture a diverse portfolio of vaccines and pharmaceutical products tailored for various animal species, including dogs, cats, and pigs. By prioritizing rigorous quality control and scientific innovation, Bioveta maintains a competitive position in the global veterinary biological market. Their commitment to animal health is supported by a robust research and development framework that ensures compliance with international veterinary standards.

The organization currently maintains a workforce of 500-1,000 employees who manage complex manufacturing operations across 4 distinct locations. These facilities are equipped with modern infrastructure designed to support high-volume production and distribution requirements. Meet Bioveta's team to understand the organizational structure and the technical expertise driving their veterinary product development. The company’s operational strategy focuses on integrating specialized engineering and technical capabilities to optimize production efficiency and maintain consistent product quality across all manufacturing lines.

Bioveta demonstrates a significant international footprint, exporting its veterinary solutions to over 90 countries, with established market penetration in regions such as Vietnam and Latin America. The company actively engages in international veterinary congresses and trade fairs to showcase its latest innovations and expand its global distribution network. With an annual revenue of $27.8M, the firm continues to leverage its technical expertise to address the evolving needs of the global veterinary health sector. By maintaining a consistent presence in key international markets, Bioveta ensures that its specialized biological products remain accessible to veterinary professionalsView more...